Public Release:  Sanford-Burnham presents cancer research at AACR

Sanford-Burnham cancer research highlights will be presented at the 105th Annual Meeting of the American Association for Cancer Research held April 5-9, 2014 in San Diego

Sanford-Burnham Medical Research Institute

LA JOLLA, Calif., April 3, 2014 -- Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors.

If you are interested in interviewing a Sanford-Burnham researcher, please contact Susan Gammon at sgammon@sanfordburnham.org.

Highlights of Sanford-Burnham's data to be presented include:

Oral Presentation

Melanoma

  • microRNA-211 modulates energy metabolism in human melanoma cells by destabilizing HIF1-alpha and down-regulating PDK4

    • Ranjan Joseph Perera, Ph.D., presentation # 978, Sunday, April 6, 3:15 p.m.- 5:15p.m., Room 31

Poster Presentations

Brain Cancer

  • Structural variants shuffle chromatin to activate GFI1 family oncogenes in medulloblastoma

    • Catherine Lee, Ph.D., presentation # LB-203, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 40

Breast Cancer

  • RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancer

    • Young Joo Jeon, Ph.D., presentation # 2440, Monday, April 7, 1 p.m.-5 p.m. Hall A-E, Poster Section 23

  • Targeting premalignant lesions for early breast cancer detection and intervention

    • Aman P. Mann, Ph.D., presentation # 3258, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 12

Cancer Metastasis

  • Membrane pseudokinase PTK7 regulates metastasis

    • Vladislav Golubkov, Ph.D., presentation # 3009, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 3

Drug Delivery Strategies

  • A tumor-specific tissue-penetrating peptide inhibits metastasis

    • Kazuki N. Sugahara, Ph.D., presentation # LB-102, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 42

  • Urokinase plasminogen activator-dependent tumor-penetrating peptide

    • Tambet Teesalu, Ph.D., presentation # 4504, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 29
  • Targeted therapies and nanoparticle strategies for selective drug delivery

    • Hong-Bo Pang, Ph.D., presentation # 5406, Wednesday, April 9, 8 a.m.-12 p.m. Hall A-E, Poster Section 28

Epigenetics

  • Mycoplasma DNA methyltransferase induces aberrant global hypermethylation and activate cancer-specific genes in human cells

    • Andrei Chernov, Ph.D., presentation # 2312, Monday, April 7, 1 p.m.-5 p.m. Hall A-E, Poster Section 18

Melanoma

  • PDK1 in melanoma development and metastasis

    • Marzia Scortegagna, Ph.D., presentation # 59, Sunday, April 6, 1 p.m.-5 p.m. Hall A-E, Poster Section 3

  • Tks adaptor proteins and invadopodia formation in the growth and metastasis of melanoma

    • Shinji Iizuka, Ph.D., presentation # 3155, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 8

  • Inhibition of melanoma growth by small molecules that attenuate P13K/PDK1 signaling and promote ATF2 mitochondrial localization

    • Giuseppina Claps, M.S., presentation # 4520, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 30

  • Interfering with interferon: An axis of ATF-2mediated chemoresistance

    • Eric Lau, Ph.D., presentation # 4901, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 9

Prostate Cancer

  • Small molecule SBI-601 inhibits Siah1/2 ubiquitin ligases, attenuates HIF1-alpha expression and growth of melanoma and prostate cancer cells

    • Yongmei Feng, Ph.D., presentation # 1795, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 33

  • The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen-receptor signaling

    • Ricardo G. Correa, Ph.D., presentation # LB-74, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 41

###

Join the conversation on Facebook and Twitter using #AACR14.

Sanford-Burnham's NCI-designated Cancer Research Center

The Cancer Center is on a mission to discover new revelations about the molecular mechanisms of cancer, with state-of-the-art drug-discovery capabilities, and a team of scientists who are relentless in pursing advances to improve the lives of cancer patients. The Cancer Center is one of seven NCI-designated basic-research cancer centers in the nation, and global leader in turning scientific discoveries into new therapeutic approaches.

About Sanford-Burnham Medical Research Institute

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at sanfordburnham.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.